Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). Fitness is a way of measuring a patient's current quality of health. With surveys, questionnaires and blood tests, we hope to create a tool that will give a good picture of patients' ability to tolerate treatment. In the future, we hope to devise the best treatment for a patient based on their "fitness".
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm I: Transplant patients | |||
| Arm II: Plasma cell dyscrasia patients |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change in Comprehensive Frailty Assessment | Responses to the Comprehensive Frailty Assessment will be assessed before and after treatment and changes will be evaluated. In transplant patients, this will be measured one year post transplant and in the non-transplant arm, this will be assessed after the second cycle of treatment. | up to 14 months |
| Measure | Description | Time Frame |
|---|---|---|
| Time to progression | We will assess time to progression for multiple myeloma patients and the relationships of those outcomes to patients' functional, cognitive and psychosocial health. | date of enrollment to date of documented clinical progression up to two years post-enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | We will assess overall survival and the relationship of those measures to patients' functional, cognitive and psychosocial health. | enrollment to date of death up to two years post-enrollment |
Inclusion Criteria:
Exclusion Criteria:
- Any medical or psychiatric condition that would make it difficult for the patient to comply with study procedures.
Not provided
Not provided
Not provided
Patients at The Ohio State University with a plamsa cell dyscrasia and/or any patient receiving a blood or marrow transplant at Ohio State will be considered for this study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ashley Rosko, MD | The Ohio State University Comprehensive Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Ohio State University Hospital East | Columbus | Ohio | 43205 | United States |
Not provided
| Label | URL |
|---|---|
| The Jamesline | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| D010265 | Paraproteinemias |
| D019337 | Hematologic Neoplasms |
| D054219 | Neoplasms, Plasma Cell |
| D008998 | Monoclonal Gammopathy of Undetermined Significance |
| D000686 | Amyloidosis |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D002318 |
| Cardiovascular Diseases |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D009371 | Neoplasms by Site |
| D006942 | Hypergammaglobulinemia |
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |